Rose BioSolutions

San Francisco, CA (GI Partners parent); operating HQ inherited from Charles River CDMO businesses
Plasmid DNA AAV Lentiviral Adenoviral CAR-T Cell Therapy Gene Editing Cell Solutions / Starting Materials
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (4) ○ EMA GMP ○ MHRA GMP

Quick Facts: Rose BioSolutions

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
San Francisco, CA (GI Partners parent); operating HQ inherited from Charles River CDMO businesses
Modalities
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Rose BioSolutions

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesPlasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press4 articles
Broad modality coverage (8 modalities)

Recent News 4 articles

news Thu, 07 Ma
GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions - PR Newswire
Source →
news Thu, 07 Ma
Moonshot AI's $2b valuation, Strooer's PE interest, Lambda's credit facility - Axios
Source →
news Sun, 18 Ma
FirstWord Lists – The 20 largest pharma M&A deals - FirstWord Pharma
Source →
news Fri, 08 Ma
GI Partners Completes Acquisition Of Charles River Laboratories’ CDMO And Cell Solutions Businesses - Pulse 2.0
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Plasmid DNA CDMOs → AAV CDMOs → Lentiviral CDMOs → Adenoviral CDMOs → CAR-T CDMOs → Cell Therapy CDMOs → Gene Editing CDMOs → Cell Solutions / Starting Materials CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
Biologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy